Rituximab

In this video, Tycel Phillips, MD, discusses challenges in diagnosing DLBCL.

SCOTTSDALE, Ariz. — Recent efforts in vasculitis research have seen both “exciting” and “frustrating” results, according to data presented at the Basic and Clinical Immunology for the Busy Clinician symposium.

In this video, Jason Westin, MD, discusses the results of the Smart Stop trial, presented at ASH Annual Meeting and Exposition.

An association with long-term complete remission was found in patients with pemphigus who used rituximab as first-line therapy, according to an extension study.

In this video, Sebastian E. Sattui, MD, MS, discusses currently available and emerging treatment options in polymyalgia rheumatica.

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab was well tolerated and showed promising efficacy in patients with relapsed or refractory chronic lymphocytic leukemia, according to data presented at ASH Annual Meeting.

Among patients with rheumatoid arthritis, the chosen course of therapy does not have an impact on the risk for developing a serious infection, according to data published in Rheumatology.

ANAHEIM, Calif. — Use of steroids and B-cell depleting therapies may lead to secondary immunodeficiencies, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

SAN DIEGO — Trimethoprim sulfamethoxazole prophylaxis halves serious infection risk in patients with granulomatosis with polyangiitis receiving B-cell depletion with rituximab, according to data presented at ACR Convergence 2023.

When it comes to naming children — at least in my generation — it was pretty straightforward.